Dr. Morgan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
777 PRB
Nashville, TN 37232Phone+1 615-936-8422
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1998
Yale-New Haven Medical CenterResidency, Internal Medicine, 1990 - 1993
Vanderbilt University School of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1994 - Present
TN State Medical License 1997 - 2024
AL State Medical License 2020 - 2020
CT State Medical License 1993 - 1994
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
Publications & Presentations
PubMed
- 28 citationsHistiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Ronald S. Go, Eric D. Jacobsen, Robert A. Baiocchi, Ilia Buhtoiarov, Erin Butler
Journal of the National Comprehensive Cancer Network. 2021-11-01 - 85 citationsIpilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multic...Catherine Diefenbach, Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson
The Lancet. Haematology. 2020-09-01 - 29 citationsAIDS-Related Kaposi Sarcoma, Version 2.2019Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin L. Ard, Robert A. Baiocchi
Journal of the National Comprehensive Cancer Network. 2019-02-01
Abstracts/Posters
- Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation CohortDavid Morgan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...David Morgan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Patient Receives Antibodies Discovered at Vanderbilt to Prevent COVID-19December 23rd, 2021- Lovelace Upgrades Staff MasksJuly 17th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
